newsfilter
← Latest News
GlobeNewswire·

Calidi Biotherapeutics Announces Pricing of $5.2 Million Underwritten Public Offering

CLDI
  • Calidi Biotherapeutics, Inc. (NYSE: CLDI) priced an underwritten public offering of 10,519,631 units, each consisting of one share of common stock (or a pre-funded warrant), one 6-month warrant, one 12-month warrant, and one five-year warrant.
  • Ladenburg Thalmann & Co. Inc. serves as the sole book-running manager for the offering.
  • Units are sold at $0.50 per unit, with pre-funded units priced at the public offering price minus a $0.001 nominal exercise price.
  • Gross proceeds from the offering are expected to be approximately $5.2 million before deducting underwriting discounts, commissions, and other estimated expenses.
  • The underwriter holds a 45-day option to purchase up to an additional 1,575,000 shares of common stock & corresponding warrants per series, or an aggregate of 4,725,000 shares, to cover over-allotments.
  • Calidi intends to use net proceeds for working capital & general corporate purposes.
  • All warrants are immediately exercisable at an exercise price of $0.50 per share.
  • The offering is expected to close on or about March 9, 2026, subject to customary closing conditions.
  • Existing warrants held by investors totaling up to 2,973,585 shares will be amended upon closing to reduce their exercise price to $0.50 per share.
  • Securities are offered pursuant to a Form S-3 shelf registration statement declared effective by the SEC on February 7, 2025.
  • Calidi is a biotechnology company headquartered in San Diego, California, developing targeted genetic medicines using its Redtail platform & pipeline candidate CLD-401.